Elsebaie and her team developed a new series on this scaffold as EGFR inhibitors, and among this series, compound St.52 (Table 10) was the most potent compound on various cancer cell lines with low toxicity on the normal cell lines WI-38, as well as this compound was arresting the cell cycle at G2/m phase in MDA-MB-468 cancer cell lines [170]. Here, EGFR is linked to cancer.